CONCLUDING RESULTS OF THE LONG-TERM PHASE-2 EXTENSION STUDY (LTE) WITH BELATACEPT AFTER KIDNEY TRANSPLANT

被引：0
|
作者：
Muehlbacher, F. [1 ]
Larsen, C. [2 ]
Grinyo, J. [3 ]
Charpentier, B. [4 ]
Blancho, G. [5 ]
Grannas, G. [6 ]
Jones-Burton, C. [7 ]
Vincenti, F. [8 ]
机构：
[1] Med Univ Wien, Vienna, Austria
[2] Emory Univ, Atlanta, GA 30322 USA
[3] Univ Krankenhaus Bellvitge, Barcelona, Spain
[4] Univ Krankenhaus Nantes, Nantes, France
[5] Univ Krankenhaus Bicetre, Le Kremlin Bicetre, France
[6] Hannover Med Sch, Hannover, Germany
[7] Bristol Myers Squibb, New York, NY USA
[8] UCSF, San Francisco, CA 94117 USA
来源：
TRANSPLANT INTERNATIONAL | 2014年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
066
引用
收藏
页码：23 / 23
页数：1
相关论文
共 50 条
  • [21] Belatacept improves Long-term Outcome after Kidney Transplantation
    Lutz, J.
    NEPHROLOGE, 2016, 11 (05): : 355 - 356
  • [22] Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results from the Long-Term Extension (LTE) of the Belatacept Evaluation of Nephroprotection and Efficacy as First-Line Immunosuppression Trial (BENEFIT) Study
    Larsen, C.
    Vincenti, F.
    Grinyo, J.
    Rice, K.
    Steinberg, S.
    Gaite, L.
    Moal, M.
    Pupim, L.
    Rostaing, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 : 312 - 312
  • [23] Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study.
    Divard, G.
    Debiais, C.
    Legendre, C.
    Aubert, O.
    Lefaucheur, C.
    Loupy, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 : 513 - 513
  • [24] Long-Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long-Term Extension of the BENEFIT Study
    Rostaing, L.
    Vincenti, F.
    Grinyo, J.
    Rice, K. M.
    Bresnahan, B.
    Steinberg, S.
    Gang, S.
    Gaite, L. E.
    Moal, M-C
    Mondragon-Ramirez, G. A.
    Kothari, J.
    Pupim, L.
    Larsen, C. P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (11) : 2875 - 2883
  • [25] 4-Year Results from the Long-Term Extension of the Belatacept BENEFIT-EXT Study
    Florman, S.
    Durrbach, A.
    Grinyo, J.
    Pestana, J. O. M.
    Rial, M. d. C.
    Vitko, S.
    Lin, C. -S.
    Harler, M. B.
    Rostaing, L.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 82 - 82
  • [26] Interim report of phase 2 long-term safety of belatacept
    Vincenti, Flavio
    Larsen, Christian
    Muehlbacher, Ferdinand
    Charpentier, Bernard
    TRANSPLANT INTERNATIONAL, 2007, 20 : 74 - 74
  • [27] Long-Term Outcomes of Thymoglobulin Induced Kidney Transplant Recipients Maintained on Tacrolimus vs Belatacept
    Kagan, Mackenzie
    Yang, Christine
    Tang, Rocky
    Tsapepas, Demetra
    Mohan, Sumit
    Cohen, David
    Ratner, Lloyd
    Hardy, Mark
    AMERICAN JOURNAL OF TRANSPLANTATION, 2024, 24 (01) : S76 - S76
  • [28] Interim report of phase 2 long-term safety of belatacept.
    Charpentier, Bernard
    Muehlbacher, Ferdinand
    Larsen, Christian
    Vincenti, Flavio
    AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 182 - 183
  • [29] Long-term results after kidney transplantation in children
    Offner, G
    Hoyer, PF
    Pichlmayr, R
    Brodehl, J
    MONATSSCHRIFT KINDERHEILKUNDE, 1996, 144 (05) : 496 - 502
  • [30] LONG-TERM RESULTS AFTER KIDNEY-TRANSPLANTATION
    ROST, A
    MOLZAHN, M
    BROSIG, W
    FIEDLER, U
    UROLOGE-AUSGABE A, 1982, 21 (05): : 299 - 305
12345